Dynavax Technologies discovers and develops products to prevent and treat infectious and inflammatory diseases. Its clinical-stage product candidates include HEPLISAV ™ Hepatitis B Vaccine, Universal Flu Vaccine , TLR Inhibitor for Lupus and Hepatitis B Therapy. The company partners with AstraZeneca, GlaxoSmithKline and other pharmaceutical companies.
Cubist Pharmaceuticals is focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIND (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. The Cubist product pipeline includes its lipopeptide program and its natural products screening program.
Coulter Pharmaceutical developed monoclonal antibody-based anti-cancer drugs that hone in on tumor cells without devastating surrounding healthy tissues. The company's flagship product was the first anti-B1 antibody-based therapy for the treatment of non-Hodgkin's lymphoma. The company merged with Corixa in December 2000, which was subsequently acquired by GlaxoSmithKline.
Corixa was formed in 1994 to develop vaccines and therapeutic products for cancer and infectious diseases based on novel approaches to immunization, stimulation, and culture of cytotoxic T cells and T helper cells. Corixa had an initial public offering in 1997, then was acquired by GlaxoSmithKline in 2005.
COR was funded to develop and commercialize innovative pharmaceutical products for the treatment and prevention of severe cardiovascular diseases, such as unstable angina, acute ischemic coronary syndrome and stroke. COR went public in 1991 and was acquired by Millennium in 2001.
Cell Genesys is focused on the development and commercialization of biological therapies for patients with cancer. The company is currently pursuing two clinical-stage product platforms — GVAX(R) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include GVAX immunotherapy for prostate cancer, GVAX immunotherapy for pancreatic cancer and leukemia, and a CG0070 oncolytic virus therapy for bladder cancer.
Aspreva identified, developed and commercialized new indications for approved drugs and late-stage drug candidates for patients living with uncommon diseases. Aspreva had an initial public offering in 2006, then was acquired by Galenica Group in 2008 and was integrated into its Vifor Pharma business unit.
Oacis provided highly customizable clinical database applications and tools for large integrated health care delivery networks. Traded on the Nasdaq , Oacis was acquired by SAIC in 1999.
Founded by recognized leaders in intrathecal therapies, CNS Therapeutics developed and brought to market safe, high-quality pharmaceuticals for site-specific delivery to the central nervous system. CNS was acquired by Covidien in 2012.
Xenon is a clinical genetics-based drug development company. Independently and through partnerships with leading global pharmaceutical companies, Xenon identifies and validates new targets for drug development and converts that knowledge into innovative and differentiated medicines. Its programs focus on indications of important unmet medical needs, including pain, anemia, iron overload, metabolic and cardiovascular disease. Xenon’s pipeline of products spans discovery through to Phase 2 clinical trials. The company is headquartered in Burnaby, British Columbia.